Next |
home / stock / agen / agen message board
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a Type B End-of-Phase 2 (EOP2) meeting in July with the U.S. Food and Drug Administration (FDA) to discuss the botensili...
2024-05-07 17:45:24 ET Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q1 2024 Earnings Call May 07, 2024 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q1 2024 Earnings Call Transcript
$100M royalty financing agreement with Ligand announced, bringing in capital via non-equity means to support critical botensilimab/balstilimab (BOT/BAL) development and launch readiness activities Company has reestablished its market compliance with Nasdaq Listing Notable clinical...